2.41
1.26%
+0.03
Omega Therapeutics Inc stock is currently priced at $2.41, with a 24-hour trading volume of 270.43K.
It has seen a +1.26% increased in the last 24 hours and a -5.68% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $2.34 pivot point. If it approaches the $2.44 resistance level, significant changes may occur.
Previous Close:
$2.38
Open:
$2.39
24h Volume:
270.43K
Market Cap:
$132.92M
Revenue:
$3.10M
Net Income/Loss:
$-97.43M
P/E Ratio:
-1.0856
EPS:
-2.22
Net Cash Flow:
$-94.38M
1W Performance:
+22.96%
1M Performance:
-5.68%
6M Performance:
+12.62%
1Y Performance:
-73.80%
Omega Therapeutics Inc Stock (OMGA) Company Profile
Name
Omega Therapeutics Inc
Sector
Industry
Phone
617-949-4360
Address
20 Acorn Park Drive, Cambridge
Omega Therapeutics Inc Stock (OMGA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-08-22 | Initiated | H.C. Wainwright | Buy |
Sep-23-22 | Initiated | Chardan Capital Markets | Buy |
Omega Therapeutics Inc Stock (OMGA) Latest News
Omega Therapeutics stock more than doubles on Novo Nordisk obesity drug research pact - MSN
MSN
Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace
BioSpace
Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace
BioSpace
Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace
BioSpace
Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace
BioSpace
Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace
BioSpace
Omega Therapeutics Inc Stock (OMGA) Financials Data
Omega Therapeutics Inc (OMGA) Revenue 2024
OMGA reported a revenue (TTM) of $3.10 million for the quarter ending December 31, 2023, a +49.23% rise year-over-year.
Omega Therapeutics Inc (OMGA) Net Income 2024
OMGA net income (TTM) was -$97.43 million for the quarter ending December 31, 2023, a +5.13% increase year-over-year.
Omega Therapeutics Inc (OMGA) Cash Flow 2024
OMGA recorded a free cash flow (TTM) of -$94.38 million for the quarter ending December 31, 2023, a +5.52% increase year-over-year.
Omega Therapeutics Inc (OMGA) Earnings per Share 2024
OMGA earnings per share (TTM) was -$1.80 for the quarter ending December 31, 2023, a +15.89% growth year-over-year.
About Omega Therapeutics Inc
Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases; to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regeneration; to down-regulate expression of the CXCL1, 2, 3, and IL-8 gene cluster; to control expression of genes implicated in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes; to down-regulate the expression of SFRP1, a protein that inhibits hair growth; and to treat non-small cell lung cancer and small cell lung cancer. It is also developing OTX-2002 to down-regulate c-Myc, an oncogene. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Cap:
|
Volume (24h):